Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

These 3 Tough Cases from the 2018 Thieves Market Underscore Need for Clinical Diligence

Thomas R. Collins  |  February 17, 2019

CHICAGO—In the Thieves Market session at the 2018 ACR/ARHP Annual Meeting, rheumatologists from around the country presented a slate of challenging cases that emphasized the importance of clinical persistence and attention to detail, and the need to consider diagnoses that might not be common or obvious. Three of them are summarized below. (Look for more…

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:2018 ACR/ARHP Annual MeetingCancercase reportCheckpoint InhibitorscyclosporineImmunoglobinleprosynifedipinepregabalintacrolimus

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD  |  February 17, 2019

As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…

Filed under:Biologics/DMARDsResearch RheumRheumatoid ArthritisSpeak Out Rheum Tagged with:OpinionSpeak Out Rheumatology

Cancer-Associated Myositis: A Case Report & Review of the Literature

Cancer-Associated Myositis: A Case Report & Review of the Literature

Osman Bhatty, MD, Rouhin Sen, MD, & Joseph Nahas, MD  |  February 17, 2019

Since it was first reported in 1916, a correlation between inflammatory myopathies and cancer has been noted in several studies. Population studies have confirmed this relationship, and the phrase cancer-associated myopathy has entered the vernacular. Over the past decade, research efforts have shifted toward revealing associations between autoantibodies and clinical phenotypes. One subset of auto-antigens…

Filed under:ConditionsMyositisOther Rheumatic Conditions Tagged with:Cancercarcinoid syndromecase reportdermatomyositis

Biosimilar ABP 798 Promising for RA

Michele B. Kaufman, PharmD, BCGP  |  February 13, 2019

A clinical trial in RA patients has established the pharmacokinetic similarity of ABP 798 and rituximab…

Filed under:Biologics/DMARDsDrug Updates

Ibuprofen an Option for Early Pain Control after Hip Replacement

Reuters Staff  |  February 13, 2019

NEW YORK (Reuters Health)—Combining paracetamol (acetaminophen) with ibuprofen does not cut postoperative use of morphine in a clinically meaningful way relative to ibuprofen alone, in patients undergoing total hip arthroplasty (THA), results of a Danish randomized trial suggest. “Although the combined use of paracetamol and ibuprofen reduced immediate postoperative morphine consumption compared with paracetamol alone…

Filed under:AnalgesicsDrug Updates Tagged with:hiphip arthroplastyIbuprofenPainPain Managementsurgerytotal hip arthroplastytotal hip replacement

Moments That the Words Don’t Reach

Philip Seo, MD, MHS  |  February 12, 2019

There are moments that the words don’t reach There is suffering too terrible to name You hold your child as tight as you can And push away the unimaginable                                     —Lin Manuel Miranda A friend of mine was killed a few days ago. By the time you read this column, the scars will have already started…

Filed under:OpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:bereavementgriefsudden bereavementsudden death

Update & Changes to the OIG Work Plan

From the College  |  February 8, 2019

Early last fall, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) released its OIG Work Plan for fiscal year 2018–2019, which is a two-year framework for the audits, inspections, evaluations and investigative activities planned in support of its vision, mission, and strategic goals and objectives to maintain HHS program integrity….

Filed under:From the CollegePractice Support Tagged with:evaluation and management (E/M)HHS programMedicare AdvantageMedicare paymentsOffice of Inspector General (OIG)OIG Work PlanOpioid misuse

RA Effectiveness Differs Among Non-TNF Inhibitors

Will Boggs, MD  |  February 5, 2019

NEW YORK (Reuters Health)—Rheumatoid arthritis (RA) outcomes are better with some non-TNF inhibitors than with others, according to French registry data. “Previously, indirect comparisons (meta-analyses) did not show any difference between biologics in terms of effectiveness,” Dr. Jacques-Eric Gottenberg from Strasbourg University Hospital, France, tells Reuters Health by email. “Our direct comparison using observational data…

Filed under:ConditionsRheumatoid Arthritis Tagged with:abataceptnon-TNF inhibitorsRheumatoid Arthritis (RA)rituximabtocilizumab

Walking Ability of OA Patients Linked to Cardiovascular Risk

Arthritis Care & Research  |  February 5, 2019

New research explores the association of the ability to walk and the risk of cardiovascular disease in OA patients compared with the general population. During the study, researchers recorded a six-minute walking distance and measured arterial stiffness of participants. The results: Even among younger people, OA patients could not walk as far as those in the general population. Also, arterial stiffness was inversely associated with walking distance, suggesting walking is important to the cardiovascular risk profile of OA patients…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis Care & ResearchCardiovascular diseaseOsteoarthritisphysical activityriskwalking

Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2019

Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…

Filed under:AnalgesicsDrug Updates Tagged with:Biologics & BiosimilarsBiosimilarsCanadaetanerceptFDAgeneric drug marketnaloxoneopioidOpioid abusePsoriatic ArthritisU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 134
  • 135
  • 136
  • 137
  • 138
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences